Using virus-like nanoparticles to improve B cell immunity against bacterial toxins and small antigens

Virus-Like Nanoparticles for Non-Capsid Antigen Delivery with Virus Structure/Functional Mimicry to Activate B Cell Immunity

NIH-funded research University of Michigan at Ann Arbor · NIH-10854794

This study is exploring a new way to help your immune system fight off serious infections by creating tiny particles that look like viruses, which can better deliver important pieces needed to activate your body's defenses against threats like anthrax and botulinum toxins.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Michigan at Ann Arbor NIH-funded
Lab location1 site (Ann Arbor, United States)
Project IDNIH-10854794 on NIH RePORTER

What this research studies

This research focuses on developing virus-like nanoparticles (NPs) that mimic the structure of viruses to enhance the delivery of small antigens, which are crucial for activating B cell immunity. Traditional nanoparticles often lack the virus-like features that are essential for effective immune response, particularly in stimulating durable antibody production. By creating nanoparticles that replicate the spiky structures of viral capsid proteins, the research aims to improve how these antigens are presented to B cells, thereby enhancing the immune response against serious threats like anthrax and botulinum toxins. The study will investigate how these virus-like features can optimize antigen delivery and retention in the lymph nodes, activate B cells, and stimulate T helper cells.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals at risk for infections caused by anthrax or botulinum toxins, as well as those with certain cancers that may benefit from enhanced immune responses.

Not a fit: Patients who do not have a compromised immune system or are not at risk for the targeted infections may not receive direct benefits from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective vaccines and therapies against bacterial infections and certain cancers by improving the immune response.

How similar studies have performed: Previous research has shown that virus-like particles can effectively stimulate immune responses, suggesting that this novel approach with virus-like nanoparticles may also yield positive results.

Where this research is happening

Ann Arbor, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anthrax disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.